Kim TY - Search Results

1

Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial.

Kim Y, Yeom CW, Lee HJ, Kim JH, Lee KM, Kim TY, Lee HB, Kim H, Im SA, Lee KH, Kim M, Han W, Moon HG, Spiegel D, Hahm BJ, Son KL. Kim Y, et al. Among authors: kim h, kim ty, kim m, kim jh. NPJ Breast Cancer. 2024 Jul 17;10(1):59. doi: 10.1038/s41523-024-00668-w. NPJ Breast Cancer. 2024. PMID: 39019875 Free PMC article.

2

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.

Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, Oh DY, Im SA, Kang GH, Bang YJ, Kim TY. Hong J, et al. Among authors: kim bs, kim ty. Cancer Chemother Pharmacol. 2011 Jun;67(6):1323-31. doi: 10.1007/s00280-010-1425-7. Epub 2010 Aug 24. Cancer Chemother Pharmacol. 2011. PMID: 20734048 Clinical Trial.

3

Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.

Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Lim KH, et al. Among authors: kim ty. Cancer Chemother Pharmacol. 2011 Oct;68(4):1017-26. doi: 10.1007/s00280-011-1584-1. Epub 2011 Feb 17. Cancer Chemother Pharmacol. 2011. PMID: 21327930 Clinical Trial.

4

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.

Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY. Han SW, et al. Among authors: kim ty. Int J Cancer. 2013 May 1;132(9):2209-16. doi: 10.1002/ijc.27888. Epub 2012 Oct 29. Int J Cancer. 2013. PMID: 23034738

5

Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data.

Lee KH, Keam B, Im SA, Kim TY, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Lee KH, et al. Among authors: kim dw, kim ty, kim jh. J Breast Cancer. 2012 Dec;15(4):427-33. doi: 10.4048/jbc.2012.15.4.427. Epub 2012 Dec 31. J Breast Cancer. 2012. PMID: 23346172 Free PMC article.

6

Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors.

Lee JK, Im SA, Lee D, Kim JY, Lim Y, Lee E, Moon HG, Kim TY, Han SW, Oh DY, Lee SH, Han W, Kim DW, Kim TY, Noh DY. Lee JK, et al. Among authors: kim jy, kim dw, kim ty. J Breast Cancer. 2013 Mar;16(1):66-71. doi: 10.4048/jbc.2013.16.1.66. Epub 2013 Mar 31. J Breast Cancer. 2013. PMID: 23593084 Free PMC article.

7

Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.

Kim JW, Im SA, Kim MA, Cho HJ, Lee DW, Lee KH, Kim TY, Han SW, Oh DY, Lee HJ, Kim TY, Yang HK, Kim WH, Bang YJ. Kim JW, et al. Among authors: kim wh, kim ma, kim ty. Int J Cancer. 2014 Jan 1;134(1):72-80. doi: 10.1002/ijc.28245. Epub 2013 Sep 17. Int J Cancer. 2014. PMID: 23649938

8

HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.

Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Kim JW, et al. Among authors: kim yj, kim ty, kim js, kim jh. Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15. Cancer Chemother Pharmacol. 2013. PMID: 23673443

9

Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.

Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY. Han SW, et al. Among authors: kim ji, kim ty, kim hp. PLoS One. 2013 May 21;8(5):e64271. doi: 10.1371/journal.pone.0064271. Print 2013. PLoS One. 2013. PMID: 23700467 Free PMC article.

10

Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.

Kim JW, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Kim JW, et al. Among authors: kim ty, kim js, kim jh. Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9. doi: 10.1007/s00280-013-2268-9. Epub 2013 Sep 15. Cancer Chemother Pharmacol. 2013. PMID: 24036907

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,640 results

Search Page

Filters